Peer-Reviewed Publication
Eur Respir Rev2024;33(171)January 31, 2024Journal Article
Towards the adoption of quantitative computed tomography in the management of interstitial lung disease.
Simon L F Walsh1, Jan De Backer2, Helmut Prosch3, Georg Langs3,4, Lucio Calandriello5, Vincent Cottin6, Kevin K Brown7, Yoshikazu Inoue8, Vasilios Tzilas9, Elizabeth Estes10,
1National Heart and Lung Institute, Imperial College, London, UK s.walsh@imperial.ac.uk.
2FLUIDDA, Antwerp, Belgium.
3Medical University of Vienna, Vienna, Austria.
4contextflow GmbH, Vienna, Austria.
5Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
6National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, Lyon, France.
7Department of Medicine, National Jewish Health, Denver, CO, USA.
8Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Japan.
95th Respiratory Department, Chest Diseases Hospital Sotiria, Athens, Greece.
10Open Source Imaging Consortium (OSIC), Saugatuck, MI, USA.
Abstract
The shortcomings of qualitative visual assessment have led to the development of computer-based tools to characterise and quantify disease on high-resolution computed tomography (HRCT) in patients with interstitial lung diseases (ILDs). Quantitative CT (QCT) software enables quantification of patterns on HRCT with results that are objective, reproducible, sensitive to change and predictive of dise…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans